AVTX
Avalo Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$7.17Close
$132.7MMarket cap
$6.75 – $22.8752-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 1 · weaker than 99% of stocks over 12 months
- Far from its high 69% below its 52-week high
- Distribution down-day volume 2.9× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
69%
1wk
up 3.5%
price change
1mo
down 53.2%
price change
12-month return
down 60%
market up 11% ·
its own down 71%
F-score
—
— Not assessed
Altman Z
-4.12
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.6×
price / book
Earnings yield
down 62.4%
EBIT / enterprise value
Cheaper than
27%
of the market · expensive
Revenue growth
down 87%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 72%
return on equity
Free cash margin
down 87217%
-$51.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
13.8%
$0.99 a day · 2×ATR $5.19
RS
1 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.35
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 76.8% over the year, from 10m to 19m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 86.6% over the year, from $441,000 to $59,000.
Last reported
Aug 6, 2026
Last shock
Oct 22, 2026-39% in one session17.1× volumeno filing matched-4% since
Financials
- Gross
- Net -132642%
- Free cash -87217%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.7M | $5.4M | $18.1M | $1.9M | $441,000 | $59,000 |
| Gross margin | 96% | 72% | 81% | 33% | — | — |
| Operating income | -$72.8M | -$82.1M | -$37.4M | -$27.4M | -$68.5M | -$72.9M |
| Net income | -$63.5M | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| Net margin | -948% | -1563% | -231% | -1640% | -7966% | -132642% |
| Earnings per share | — | — | -$1,062.65 | -$113.58 | -$4.69 | -$5.84 |
| Free cash flow | -$40.6M | -$71.0M | -$26.8M | -$30.7M | -$49.1M | -$51.5M |
| Free cash margin | -606% | -1315% | -149% | -1595% | -11124% | -87217% |
| Cash | $18.9M | $54.6M | $13.2M | $7.4M | $134.5M | $15.9M |
| Long-term debt | $0 | $32.8M | $13.5M | $0 | — | — |
| Shareholders' equity | $24.6M | $23.1M | -$10.9M | $7.3M | $133.0M | $83.0M |
| Shares outstanding | 315.02k | 473.93k | 39.29k | 801.75k | 10.47m | 18.51m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 23, 2026 | Annual ↗ | Dec 31, 2025 | 82d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 29, 2024 | Annual ↗ | Dec 31, 2023 | 89d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 23, 2026 | Director or officer change ↗ |
| Jun 16, 2026 | Other events ↗ |
| Jun 12, 2026 | Unregistered share sale · Holder rights changed · Director or officer change · Charter or bylaws ↗ |
| Jun 8, 2026 | Director or officer change · Shareholder vote ↗ |
| May 13, 2026 | Results ↗ |
| May 7, 2026 | Material agreement · Results · Regulation FD ↗ |
| May 5, 2026 | Other events ↗ |
| Apr 28, 2026 | Material agreement · Regulation FD ↗ |
| Mar 27, 2026 | Director or officer change ↗ |
| Mar 23, 2026 | Results ↗ |
| Jan 12, 2026 | Results · Other events ↗ |